Clinical Mondays: An Exciting Approach Towards Cancer Treatment – The Babak Lab
The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: An Exciting Approach Towards Cancer Treatment.
An interesting study published in NEJM Evidence introduces an AI-driven predictive model to personalize hormone therapy (androgen deprivation therapy, ADT) for prostate cancer patients. By analyzing digital pathology images and clinical data from over 5,700 patients across five randomized trials, the model identifies which men with localized prostate cancer are likely to benefit from ADT combined with radiotherapy – and which can avoid its significant side effects.
Key Takeaways:
- 34% of patients were “model-positive” and saw a 10.5% absolute reduction in 15-year metastasis risk with ADT.
- 66% were “model-negative” and derived no benefit from ADT, sparing them unnecessary toxicity.
- Validated on patients in phase 3 clinical trial.
Link to the full article.”
Maria (Masha) Babak, Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong, shared a post by The Babak Lab, adding:
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023